Topical Clonazepam for Burning Mouth: Relief and Prescription Risks

A prescription for clonazepam held in the mouth raises two separate questions: how much pain relief to expect, and what monitoring the medicine needs.

First confirm the diagnosis. NIDCR advises an examination and medical history to rule out other causes of mouth pain, including infection, irritation and tooth or gum problems. Depending on the findings, tests can assess medical conditions, allergies or saliva flow. Treating an underlying cause may relieve the burning.¹

What the older placebo trials measured

The 2004 multicentre trial² enrolled 48 people, including 44 women; 41 completed it. Participants held clonazepam or placebo in the mouth and spat out the saliva. Over 14 days, average pain fell 2.4 points with clonazepam versus 0.6 with placebo on a 0–10 scale. The difference was statistically significant, including in an analysis accounting for all enrolled participants. Roche supplied tablets; the university hospital provided financial support.²

The 2010 Barcelona study³ enrolled 66 people, including 64 women, with 33 per group. At one month, the authors reported 23 of 33 clonazepam participants versus four of 33 placebo participants with at least 50% symptom reduction. However, five versus one were symptom-free, a difference that was not statistically significant. Many participants used other psychoactive medicines, and both groups received supportive psychotherapy.³

These are different outcomes to discuss at a review: a lower pain score, fewer painful hours, and no symptoms. Ask which outcome your prescriber expects and when it will be assessed.

A newer small study complicates the picture

A 2026 University of São Paulo doctoral thesis reported a double-blind trial with 24 people, 12 per group, testing clonazepam mouth rinse against placebo for seven weeks, with follow-up through 90 days after treatment.⁴

Pain improved over time in both groups. The report describes differing pain trajectories, but individual follow-up comparisons did not show a statistically significant advantage over placebo. Follow-up losses and the small sample limit interpretation. The cited report is a doctoral thesis. Its preparation differed from those in the older tablet studies. CAPES supported the doctoral scholarship.⁴

Holding it in the mouth still needs a drug-safety discussion

The 2004 study² measured clonazepam in blood in a small subgroup. In the 2010 study³, five clonazepam participants reported sleepiness. Neither supports assuming that spitting out saliva prevents all systemic effects.²³

In the US, the tablet label covers certain seizure disorders and panic disorder; burning mouth treatment is off-label. Its boxed warning addresses abuse, misuse, addiction, physical dependence and withdrawal. Combining it with opioids can cause profound sedation and dangerous breathing suppression. Alcohol and other sedating medicines also matter; the label cautions about driving and machinery.⁵

Bring your full medicine list, including sleep aids and opioid pain medicines. Ask for written instructions specific to the prescribed preparation, what to do about drowsiness, and a review date. After continued use, abrupt stopping or rapid dose reduction can cause dangerous withdrawal, including seizures; discuss an individual stopping plan.⁵

Take a symptom record to the review

Record the time of burning, its severity, eating or speaking difficulties, treatment times and any sleepiness. Bring the starting scores so the follow-up has something concrete to compare.

The burning-mouth discussion in “Dry Mouth, Strange Taste” in Is It My Breath? explains the need to investigate other causes and the limits of treatment evidence. Our burning mouth overview covers the initial assessment.